Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Frequently asked questions
What sector does Pharmicell (005690) operate in?
Pharmicell belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pharmicell (005690) current stock price?
As of the latest data, Pharmicell stock price is ₩9,400, with a previous close of ₩9,800. Pharmicell lost -₩400 in the last trading session, representing a -4.08% loss.
What is Pharmicell (005690) current market capitalization?
Pharmicell market cap is approximately 564.04 billion.
What is Pharmicell (005690) Earnings Per Share (EPS)?
The trailing EPS is -₩446, and the forward EPS is ₩1,270.
What is Pharmicell (005690) EBITDA?
Pharmicell EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 13.95 billion.
Does Pharmicell (005690) pay dividends?
Yes. Pharmicell pays annual dividends with an annualized yield of 0.53% and an estimated annual payout of ₩50 per share.
When is the next ex-dividend date for Pharmicell (005690)?
The next ex-dividend date is scheduled for December 29, 2026.
What is Pharmicell (005690) beta (volatility) score?
Pharmicell has a beta of 0.609, indicating lower volatility than the overall market.
